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Objective. To determine whether autophagy is involved in the degradation of misfolded HLA-B27 in experimental spondyloarthritis.
Methods. Bone marrow-derived macrophages from HLA-B27/human b 2 -microglobulin (hb 2 m)-transgenic rats were incubated in the presence or absence of interferon-c and proteasome or autophagy inhibitors. Immunoprecipitation, immunoblotting, and immunofluorescence analysis were used to measure HLA-B27 heavy chains and autophagy. Autophagy was induced using rapamycin. Macrophages from HLA-B7/hb 2 m-transgenic and wild-type rats were used as controls.
Results. HLA-B27-expressing macrophages showed phosphatidylethanolamine-conjugated microtubuleassociated protein 1 light chain 3B levels similar to those in both control groups, before and after manipulation of autophagy. Blocking autophagic flux with bafilomycin resulted in the accumulation of misfolded HLA-B27 dimers and oligomers as well as monomers, which was comparable with the results of blocking endoplasmic reticulum-associated degradation (ERAD) with the proteasome inhibitor bortezomib. HLA-B7 monomers also accumulated after blocking each degradation pathway. The ubiquitin-to-heavy chain ratio was 2-3-fold lower for HLA-B27 than for HLA-B7. Activation of autophagy with rapamycin rapidly eliminated~50% of misfolded HLA-B27, while folded HLA-B27 or HLA-B7 monomeric heavy chains were minimally affected.
Conclusion. This study is the first to demonstrate that both autophagy and ERAD play roles in the elimination of excess HLA class I heavy chains expressed in transgenic rats. We observed no evidence that HLA-B27 expression modulated the autophagy pathway. Our results suggest that impaired ubiquitination of HLA-B27 may play a role in the accumulation of misfolded disulfide-linked dimers, the elimination of which can be enhanced by activation of autophagy. Manipulation of the autophagy pathway should be further investigated as a potential therapeutic target in spondyloarthritis.
HLA-B27 is strongly associated with the development of spondyloarthritis (SpA), in particular axial disease that progresses to ankylosing spondylitis (1) . Although the pathogenic mechanisms remain incompletely understood, abnormal properties of the HLA-B27 heavy chain have been implicated (2, 3) . HLA-B27 exhibits a propensity to misfold and dimerize in the endoplasmic reticulum (ER) (4) (5) (6) and to form b 2 -microglobulin (b 2 m)-free homodimers on the cell surface (2) . HLA-B27 has also been implicated in dendritic cell dysfunction (7, 8) . Each of these properties has been mechanistically linked to the interleukin-23 (IL-23)-IL-17 axis, where several additional risk genes are located (9) , which supports a central role for this axis in pathogenesis (10) . Indeed, when HLA-B27 is expressed in rats along with human b 2 m (hb 2 m), an SpAlike disease that is dependent on gut microbiota develops spontaneously (11) , with striking activation of the IL-23-IL-17 axis in the inflamed gut and involved joints (12, 13) . IL-17A was recently established as a therapeutic target in ankylosing spondylitis (14) , and there is evidence that blocking a subunit of IL-23 (shared with IL-12) may be beneficial (15) , which underscores the importance of this axis in human disease and the relevance of this animal model for analyzing pathogenic mechanisms.
The abnormal behavior of HLA-B27 in the ER involves the formation of disulfide-linked dimers by newly synthesized heavy chains (5, (16) (17) (18) . These misfolded heavy chains bind to the ER chaperone BiP (also known as GRP78; encoded by HSPA5) and accumulate, and under certain circumstances can activate an ER stress response that alters immune signaling pathways (17, 19) . There are ER quality control (ERQC) pathways that orchestrate the elimination of misfolded proteins, usually mitigating the threat that they pose to ER homeostasis (20) . HLA-B27 has been shown to undergo ER-associated degradation (ERAD) (4, 21, 22) , which involves dislocation of target proteins from the ER membrane, with retrotranslocation and ubiquitination in the cytosol, where they are degraded by proteasomes (23) . Although the machinery differs for different proteins, ERAD of HLA class I and HLA-B27 is dependent on E3 ubiquitin ligase hydroxymethylglutarylcoenzyme A reductase degradation 1 (HRD-1) (also known as synoviolin; encoded by SYVN1), and the E2 ubiquitin-conjugating enzyme E2 J1 (UBE2J1) (21, 22) . Depletion of HRD-1 as well as other components of the ERAD pathway (e.g., X-box binding protein 1, degradation in endoplasmic reticulum protein 1 [derlin-1], and derlin-2) promotes the accumulation of misfolded HLA-B27 heavy-chain dimers in HeLa cells. Moreover, forced overexpression of ER degradation-enhancing amannosidase-like protein 1 (EDEM1), which targets unsalvageable ER glycoproteins for ERAD, or up-regulation of the ERAD pathway, enhances the elimination of HLA-B27 dimers (22) . Despite the fact that ERAD serves a role in ERQC for HLA-B27, it is insufficient to prevent the accumulation of misfolded dimers in cells expressing this HLA class I molecule (5, 17) .
Autophagy delivers cytoplasmic organelles and macromolecules to lysosomes for destruction (24) and is important for cellular survival during short-term starvation, recycling of damaged organelles, differentiation of several cell types, and the clearance of intracellular microbes (24) (25) (26) (27) . In macroautophagy (generally referred to as autophagy), a double membrane is formed around targeted organelles or aggregated proteins, creating an autophagosome, which subsequently fuses with lysosomes (28) . Autophagy is important for the elimination of terminally misfolded cytosolic and ER luminal proteins that are resistant to proteasomal degradation (29, 30) and more recently was shown to degrade nonaggregated membrane proteins that are resistant to ERAD (31) . This prompted us to investigate whether autophagy is also involved in the degradation of misfolded forms of HLA-B27.
Herein, we show that autophagy as well as ERAD contribute to the elimination of misfolded disulfide-linked HLA-B27 heavy chains. Moreover, activation of autophagy with rapamycin can be used to promote degradation of misfolded HLA-B27. We also show that HLA-B27 dimers are poorly ubiquitinated relative to the control substrate HLA-B7, suggesting that the formation of disulfidelinked dimers may be an impediment to efficient ERAD. These results raise the possibility that the autophagy pathway might be exploited for therapeutic benefit.
MATERIALS AND METHODS
Animals. Hemizygous HLA-B*27:05 and hb 2 mtransgenic (B27-transgenic) rats carrying 55 copies of HLA-B27 and 66 copies of hb 2 m in the 33-3 locus on the Lewis background were used, as described previously (32) . The HLA-B*07:02 and hb 2 m-transgenic (B7-transgenic) rat line (Lewis rats carrying the 120-4 transgene locus) was kindly provided by Joel Taurog (Dallas, TX). Homozygous B7-transgenic rats (i.e., 52 copies of HLA-B7 and 10 copies of hb 2 m) were used. Transgene-negative littermates or Lewis rats were used as wild-type (WT) rats. Rats were bred and housed in Association for Assessment and Accreditation of Laboratory Animal Care-approved facilities at the Bethesda campus of the National Institutes of Health. All animal experiments were preapproved by the Animal Care and Use Committee at the National Institute of Arthritis and Musculoskeletal and Skin Disease.
Isolation of bone marrow-derived macrophages (BMMs). Bone marrow was obtained from the tibias and femurs of euthanized 8-12-week-old Lewis rats. To derive macrophages, nonadherent BM monocytes were incubated at 5 9 10 6 cells/ml in high-glucose Dulbecco's modified Eagle's medium (Thermo Fisher Scientific) supplemented with 10% fetal calf serum (Thermo Fisher Scientific), 100 units/ml penicillin, 100 lg/ml streptomycin (Thermo Fisher Scientific), and 20 ng/ml macrophage colonystimulating factor (PeproTech). Cells were cultured at 37°C in a humidified atmosphere containing 5% CO 2 . The medium was changed every other day. Cells were used for the experiments on day 7.
Reagents and antibodies. Interferon-c (IFNc) was used at a concentration of 50 ng/ml in all experiments. For autophagy modulation. the following reagents were used: rapamycin (InvivoGen), bafilomycin A1 (InvivoGen), and chloroquine diphosphate salt (Sigma-Aldrich). Bortezomib (Cell Signaling Technology) was used to block proteasomal degradation of proteins and thus ERAD. For immunoblotting and immunoprecipitation analysis, the following antibodies were used: rabbit anti-light chain 3B (anti-LC3B) antibody (Sigma-Aldrich), rabbit anti-b-tubulin antibody (Abcam), goat anti-GRP78/HSPA5 antibody (R&D Systems), mouse antibody HC10 (33) , and rat antibody 3B10.7 (5), recognizing HLA class I. For flow cytometry, the ME1 antibody was used. ME1 recognizes HLA-B27 and other B alleles, but not rat HLA class I. For immunoblotting, horseradish peroxidase (HRP)-conjugated anti-rabbit, anti-goat, anti-mouse (R&D Systems), and anti-rat (SouthernBiotech) antibodies were used. For immunofluorescence experiments, rabbit anti-LC3B antibody (Cell Signaling Technology) and Alexa Fluor 488-conjugated donkey anti-rabbit secondary antibody (Life Technologies) were used.
Immunofluorescence. For immunofluorescence staining, macrophages from WT, B7-transgenic, or B27-transgenic rats were incubated with different autophagy modulators for 2 hours. Cells were then fixed and permeabilized with ice-cold methanol and incubated with 5% normal goat serum (Life Technologies) for 1 hour at room temperature, followed by overnight incubation at 4°C with the primary antibody (anti-LC3B; Cell Signaling Technology). After washing with phosphate buffered saline (PBS), cells were incubated with the fluorescence-labeled secondary antibody (Alexa Fluor-conjugated anti-rabbit Alexa 488) for 2 hours at room temperature. DAPI (Sigma-Aldrich) was used to visualize the nucleus. Cells were visualized with a Leica SP5 NLO confocal fluorescence microscope (Leica Microsystems) at 639 magnification.
Immunoprecipitation and immunoblotting. To prevent spontaneous sulfhydryl bond formation and breakdown, at the end of each experiment and immediately prior to harvesting, cells were treated for 20 minutes with 10 mM methyl methanethiosulfonate (Thermo Scientific) in ice-cold PBS on ice. Cells were then lysed for 20 minutes on ice in 25 mM Tris, 150 mM NaCl, 1 mM EDTA, 1% Nonidet P40, and 5% glycerol, pH 7.4 (Thermo Fisher Scientific) containing complete EDTA-free proteinase inhibitor cocktail tablets (Roche). Nuclei were removed by centrifugation at 13,000g for 10 minutes, and supernatants were collected and used for immunoblotting or immunoprecipitation analysis. For immunoblotting, lysates were diluted with 59 nonreducing sample buffer (Thermo Fisher Scientific) and boiled for 5 minutes at 95°C. In order to reduce samples, 49 sample buffer containing dithiothreitol (Sigma-Aldrich) was used. Proteins were separated on 4-20% Tris-glycine gels (Bio-Rad).
After immunoblotting, the PVDF membrane was blocked with 5% milk in PBS containing 0.02% Tween (PBS-Tween; PBST) buffer for 1 hour and incubated overnight at 4°C in 5% bovine serum albumin (BSA)/PBST with the following primary antibodies: 3B10.7 (to detect HLA class I heavy chains), goat anti-BiP (R&D Systems), rabbit anti-LC3B (Sigma-Aldrich), rabbit anti-ubiquitin (Cell Signaling Technology), and rabbit antia-tubulin (Abcam). After 3 washes, the membrane was incubated with the respective HRP-conjugated secondary antibodies (R&D Systems) for 1 hour at room temperature. Proteins were visualized using Pierce ECL Western Blotting Substrate (Thermo Fisher Scientific). Prior to immunoprecipitation, the sample protein concentration was measured using a Bio-Rad DC Protein Assay. Equal amounts of protein were used for the immunoprecipitations. Immunoprecipitation with the HC10 antibody was performed using a Pierce Crosslink IP kit (Thermo Fisher Scientific) according to the manufacturer's guidelines. A Pierce Ubiquitin Enrichment Kit (Thermo Fisher Scientific) was used to immunoprecipitate polyubiquitin protein conjugates.
Flow cytometry. To measure cell surface expression of HLA-B27, macrophages were washed and incubated with 5% BSA (Sigma-Aldrich) in PBS at 4°C for 30 minutes and then incubated with allophycocyanin-labeled HC10 antibody or Pacific Blue-labeled ME1 antibody for 30 minutes at 4°C. Cells were washed and analyzed by fluorescence-activated cell sorting using a Beckman Coulter CyAn ADP analyzer.
Statistical analysis. Statistical analysis was performed using Student's t-test. P values less than 0.05 were considered significant. Data were analyzed using GraphPad version 6.0b.
RESULTS
Contribution of autophagy and ERAD to the degradation of HLA-B27. To determine whether autophagy plays a role in the degradation of HLA-B27, we assessed BMMs from HLA-B27-transgenic rats. BMMs were derived in vitro in the absence of proinflammatory cytokines, and under these conditions they express low levels of b 2 m-free HLA-B27 heavy chains (17, 34) . To determine the relative contribution of autophagy and ERAD to the elimination of HLA-B27, BMMs were incubated in the absence or presence of IFNc for 21 hours to up-regulate HLA-B27 expression, and bafilomycin A1 or bortezomib was added for the final 3 hours.
Bafilomycin A1 inhibits vacuolar H + -ATPase, which prevents the maturation of autophagic vacuoles and autophagic degradation of proteins (35) . Bortezomib binds to the active sites of the b5 and b1 subunits of the proteasome (36) and inhibits proteasomal degradation of proteins, which is essential for ERAD (37) . Cells were lysed, and HLA-B27 heavy chains were immunoprecipitated from equal amounts of protein with the HC10 antibody, separated by nonreducing sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE), and Figure 1 . Accumulation of HLA-B27 with inhibition of autophagy or endoplasmic reticulum-associated degradation (ERAD). A, Bone marrow-derived macrophages were stimulated with interferon-c (IFNc) and then were treated with bafilomycin (Baf) 100 mM or bortezomib (Bor) 10 nM or were not treated. Bafilomycin was used to block the autophagy pathway, and bortezomib was used to block the ERAD pathway. Untreated cells and cells treated with only bafilomycin or bortezomib were used as controls. Immunoprecipitation (IP) studies and immunoblotting (IB) with HC10 and 3B10.7 (anti-HLA and anti-BiP, respectively) were performed as described in Materials and Methods. Dimers and oligomers were visualized on nonreducing sodium dodecyl sulfate-polyacrylamide gel electrophoresis, while BiP was analyzed under reducing conditions. For quantification, sample values were normalized to untreated or IFNc-treated controls, as indicated, and expressed as the fold change. Bars show the mean AE SEM (n = 5 independent experiments). B, HLA-B27-expressing C1R cells were stimulated for 3 hours with bafilomycin or bortezomib prior to immunoprecipitation and immunoblotting. Bars show the mean AE SEM (n = 6 experiments using the same cell line). The IgG-labeled lanes show the background when immunoprecipitation was performed with nonspecific IgG alone. Representative immunoblots are shown. * = P < 0.05. visualized by immunoblotting with the anti-HLA class I antibody 3B10.7 ( Figure 1 ). HC10 has previously been shown to recognize HLA-B (and HLA-C) heavy chains that are not associated with b 2 m (38), including unfolded and misfolded forms that exist as monomers, dimers, or oligomers (5) . In rat cells that lack other HLA-B/C alleles, only HLA class I expressed from the transgene was recognized. Coprecipitating BiP bound to HLA-B27 heavy chain was also visualized by immunoblotting after running an aliquot of the same HC10 immunoprecipitate on a separate gel.
In the absence of IFNc, relatively little b 2 m-free HLA-B27 heavy chain was detected in immunoprecipates from macrophages ( Figure 1A ). HLA-B27 was strongly up-regulated by IFNc, resulting in the accumulation of heterogeneous disulfide-linked dimers and oligomers of HLA-B27 (also referred to as misfolded forms), as well as monomers (also referred to as free heavy chains) (Figure 1A ). Proteasome inhibition with bortezomib resulted in a 1.5-fold increase and a 1.7-fold increase in dimeric and oligomeric forms of HLA-B27, respectively. This confirms previous findings that misfolded HLA-B27 undergoes ERAD in human cells (4, 21, 22) and extends these findings to HLA-B27-transgenic rats.
Blockade of autophagic flux with bafilomycin induced a similar (1.3-fold and 1.4-fold) increase in HLA-B27 dimers and oligomers, respectively, with the effects of proteasome inhibition being slightly more prominent. Bafilomycin and bortezomib also led to a 1.2-fold and a 1.3-fold increase, respectively, in the accumulation of monomers. Inhibition of autophagy and ERAD also resulted in the accumulation of BiP in HLA-B27 heavy chain immunoprecipitates (2-3-fold). BiP has been shown to preferentially bind to HLA-B27 dimers (16) and accumulates with misfolded HLA-B27 in the ER (17) and has been shown to preferentially accumulate with HLA-B27 dimers (16) . Treatment with each inhibitor alone in cells that were not treated with IFNc did not lead to accumulation of HLA-B27, indicating that neither autophagy nor ERAD is contributing significantly to rapid heavy chain degradation at baseline. Similar experiments were performed with wortmannin and LY294002, both of which inhibit autophagosome formation by blocking phosphatidylinositol 3-kinase. We obtained results similar to those for bafilomycin, supporting involvement of the autophagy pathway (Navid F, et al: unpublished observations).
We next sought to determine whether transfected cells that constitutively express HLA-B27 (e.g., C1R.B27 cells) in the absence of proinflammatory cytokines also use autophagy to degrade misfolded heavy chains. We previously showed that C1R.B27 cells eliminate a proportion of HLA-B27 through the ERAD pathway, with deglycosylated heavy chains accumulating in the cytosol after 3 hours of proteasome inhibition (4). In the current study, we treated C1R.B27 cells for 3 hours with bortezomib or bafilomycin and then assessed the accumulation of various forms of HLA-B27 heavy chain ( Figure 1B) . Both bafilomycin and bortezomib increased the accumulation of HLA-B27, with the effect on dimers being most prominent, followed by oligomers and monomers. Coprecipitating BiP also increased. Bafilomycin was more effective than bortezomib at inhibiting HLA-B27 degradation and causing accumulation of heavy chains bound to BiP in C1R.B27 cells.
To demonstrate that both inhibitors were blocking the destruction of proteins targeted for degradation, we examined ubiquitinated complexes in whole cell lysates. In both rat BMMs and C1R cells, incubation with bafilomycin or bortezomib for 3 hours led to accumulation of ubiquitinated proteins compared with untreated cells or cells treated with IFNc alone (see Supplementary  Figure 1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40414/ abstract). Only bafilomycin caused an increase in LC3B-II, a marker of autophagy (35, 39) , indicating that bortezomib was not affecting autophagic flux under these conditions (see Supplementary Figure 1 ). Taken together, these results show that in addition to using ERAD, rat BMMs as well as C1R cells use the autophagy pathway to degrade misfolded dimers and oligomers, as well as some monomers of HLA-B27.
No alteration in autophagy by HLA-B27 expression in rat BMMs. The involvement of autophagy in HLA-B27 degradation raised the possibility that this pathway might be altered in HLA-B27-expressing rat cells. To test this, BMMs from WT, HLA-B27-transgenic, and HLA-B7-transgenic rats were incubated with bafilomycin or chloroquine to block autophagic flux, or with rapamycin, which activates autophagy by inhibiting mammalian target of rapamycin (mTOR). Changes in LC3B-II levels were monitored as a marker for autophagic flux (39) . The LC3B protein (encoded by MAP1LC3B) is cleaved at the C-terminus forming LC3B-I, which is localized in the cytosol. During the initiation of autophagy, LC3B-I is conjugated to phosphatidylethanolamine to form LC3B-II, which becomes embedded in the autophagosome membrane. Hence, an increase in LC3B-II is widely used as a measure of autophagy, because it reflects the number of autophagosomes. The antibody used for immunoblotting revealed 2 bands representing LC3B-I and LC3B-II (Figure 2A ). LC3B-II migrates faster due to the phosphatidylethanolamine moiety. Increased accumulation of LC3B-II can reflect activation of autophagy (until autophagosomes are destroyed and steady state is reached) or inhibition of the later stages of autophagy, which leads to accumulation of autophagosomes. Therefore, inhibitors (chloroquine and bafilomycin) as well as activators of autophagy (rapamycin) lead to increases in LC3B-II under these conditions (13) .
In the current study, immunoblotting showed no differences in LC3B-II levels between macrophages from untreated WT, HLA-B27-transgenic, and HLA-B7-transgenic mice (Figure 2A) . Within each group, chloroquine, bafilomycin, and rapamycin all increased LC3B-II accumulation, as expected (Figure 2A ), but there were no differences between genotypes, indicating that the autophagy pathway is not altered by baseline (unstimulated) HLA-B27 or HLA-B7 expression. This was further confirmed by immunofluorescence staining of LC3B-II in macrophages. Although chloroquine, bafilomycin, and rapamycin all increased vesicular staining of LC3B-II, there were no apparent differences between genotypes ( Figure 2B ). We also sought to determine whether treatment of cells with IFNc would expose differences between genotypes due to either HLA-B27 or HLA-B7 up-regulation. Again, there were no differences between WT and HLA class Iexpressing cells incubated with bafilomycin alone, IFNc alone, or both ( Figure 2C ). It should be noted that activating autophagy in macrophages requires high concentrations of rapamycin, which could be toxic (40) . Therefore, we confirmed that the dose we used (25 lM) did not affect macrophage viability after 2-4 hours of incubation (Colbert RA, et al: unpublished observations). These data indicate that the autophagy pathway is not grossly altered by HLA-B27 or HLA-B7 expression in rat macrophages.
Poor ubiquitination of HLA-B27 heavy chains relative to HLA-B7. Many proteins that misfold in the ER are efficiently degraded by ERAD, while others (e.g., HLA-B27) can accumulate and result in cellular dysfunction (30, 41) . Resistance to ERAD is incompletely understood, but one contributing factor is the formation of aberrant intermolecular disulfide bonds, which results in dimerization or oligomerization (42) . Because ERAD requires ubiquitination, we sought to determine whether HLA-B27 heavy chains were ubiquitinated, using HLA-B7 for comparison. Homozygous HLA-B7-transgenic rats were used so that the amount of HLA class I heavy chain would be comparable with the amount expressed in HLA-B27-transgenic rats and up-regulated in response to IFNc (34) . In experiments similar to those shown in Figure 1 , we observed that HLA-B7 heavy-chain monomers accumulated in IFNc-treated cells when autophagy or ERAD was inhibited ( Figure 3A) , indicating that excess HLA-B7 heavy chains are also being eliminated by quality control pathways.
Next, aliquots of the same HC10 immunoprecipitates shown in Figure 3A were subjected to SDS-PAGE and probed for ubiquitin. As shown in Figure 3B , highly ubiquitinated HLA class I heavy chains accumulated when ERAD was inhibited and to a lesser extent when autophagy was blocked. We determined the ratio of ubiquitinated heavy chain in the HC10 immunoprecipitates ( Figure 3B ) to total heavy chain in the same immunoprecipitates Figure 2 . Autophagy in rat macrophages expressing HLA class I transgenes. A, Bone marrow-derived macrophages (BMMs) from wild-type (WT), HLA-B27-transgenic (B27-Tg), and B7-Tg rats were not treated or were stimulated with rapamycin (Ra) (25 lM) to induce autophagy, chloroquine (C) (50 lM), or bafilomycin (400 nM) to block autophagic flux. Cells were collected 2 hours later and lysed, and lysates were analyzed by immunoblotting with anti-microtubule-associated protein 1 light chain 3B (anti-LC3B). Anti-b-tubulin (a-bTub) was used as a loading control. The immunoblot is representative of 3 independent experiments. B, Macrophages treated as described in A were analyzed by immunofluorescence staining with anti-LC3B (green), which has a stronger affinity for phosphatidylethanolamine-conjugated microtubule-associated protein 1 light chain 3B (LC3B-II). Nuclei were visualized by DAPI staining (blue). Immunofluorescence was evaluated using confocal imaging. Images are representative of 3 independent experiments. Original magnification 9 63. C, BMMs from WT, B27-transgenic, and B7-transgenic rats were incubated without or with IFNc (50 ng/ml) for 24 hours, followed by incubation for an additional 24 hours with bafilomycin (10 nM). LC3B-II expression was determined by immunoblotting, as described in A. Values are the mean AE SEM and are representative of 3 independent experiments. sAb = secondary antibody (see Figure 1 for other definitions).
( Figure 3A ) and plotted the ubiquitin-to-heavy chain ratio for both HLA class I molecules ( Figure 3C ). These quantitative data revealed several important points. First, the ubiquitin-to-heavy chain ratio was 2-3-fold greater for HLA-B7 than for HLA-B27. This must reflect a greater number of ubiquitinated heavy chains, because the alternative of more ubiquitin per heavy chain was not reflected in the patterns shown in Figure 3B (i.e., no shift toward higher molecular weight complexes for HLA-B7). Second, the ubiquitin-to-heavy chain ratio increased with blockade of autophagy or ERAD but was most pronounced when ERAD was inhibited. This is consistent with ERAD being the primary pathway for degradation of ubiquitinated heavy chains. Third, even without blocking degradation (i.e., IFNc up-regulation alone), ubiquitinated heavy chains were more abundant for HLA-B7 than for HLA-B27 (Figures 3B and C) . Note that the diminished recovery of b 2 mfree HLA-B7 heavy chains compared with HLA-B27 (Figure 3A) is due to more efficient folding and loss of HC10 reactivity, as described previously (34) .
To gain more insight into the predominant form of heavy chain that is ubiquitinated, we used an anti-ubiquitin antibody to perform immunoprecipitations, followed by immunoblotting with the anti-HLA class I antibody 3B10.7. Significantly more HLA-B7 was recovered compared with HLA-B27 ( Figure 3D) , which is consistent with the increased ubiquitin-to-heavy chain ratio for HLA-B7 ( Figure 3C) . Furthermore, the predominant form of HLA-B27 that was recovered was dimers ( Figure 3D ), whereas monomers were recovered for HLA-B7. Taken together, these data indicate that there are major differences in how HLA-B7 and HLA-B27 heavy chains are managed by quality control pathways in rat BMMs. Notably, HLA-B27 heavy-chain dimers (and monomers) were inefficiently ubiquitinated compared with HLA-B7.
Elimination of misfolded and unfolded forms of HLA-B27 by activation of autophagy. We next sought to determine whether activation of autophagy would enhance the degradation of HLA-B27. BMMs were treated with IFNc for 6 hours to up-regulate HLA class I expression, washed to remove IFNc, and incubated for an additional 2 hours in the absence or presence of rapamycin to activate autophagy (see Supplementary Figure 2 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wi ley.com/doi/10.1002/art.40414/abstract). HLA-B27 heavy chains were then immunoprecipitated with HC10 and visualized by immunoblotting. Oligomers and dimers of HLA- Figure 3 . Differential ubiquitination of HLA-B7 and HLA-B27 heavy chains. A, Bone marrow-derived macrophages expressing HLA-B27 and HLA-B7 were treated for 21 hours with IFNc and then for an additional 3 hours in the absence or presence of bafilomycin (100 nM) or bortezomib (10 nM). HLA class I heavy chains immunoprecipitated with HC10 were analyzed under nonreducing or reducing conditions as indicated and visualized by immunoblotting using 3B10.7. B, HC10 immunoprecipitates from the experiment described in A were immunoblotted with anti-ubiquitin antibody (aUb). C, The ratio of ubiquitinated material in the HC10 immunoprecipitates to total heavy chain (Ub:HC) in the same immunoprecipitates was quantitated under nonreducing conditions and plotted for HLA-B27 and HLA-B7 under each experimental condition. Bars show the mean AE SEM (n = 5 experiments). * = P < 0.05; ** = P < 0.005 versus IFNc alone. D, Cells treated as described in A were used to immunoprecipitate all ubiquitinated material, and immunoblotting with HC10 was used to visualize heavy chains. Tg = transgenic (see Figure 1 for other definitions). Figure 4 . Effect of activating autophagy with rapamycin (Ra) on misfolded HLA-B27. Bone marrow-derived macrophages were incubated without or with IFNc (50 ng/ml) for 6 hours, washed, and treated without or with rapamycin (25 lM) for 2 hours. HC10 was used to immunoprecipitate unfolded/misfolded heavy chains, followed by immunoblotting with 3B10.7 (anti-HLA). Coprecipitating BiP was measured using an aliquot of the immunoprecipitate run on a separate reducing gel. Immunoblots depict representative results. The boxed area shows longer exposure of the outlined areas. Bars show the mean AE SEM (n = 6 independent experiments). Dimers, oligomers, and BiP were quantitated only in IFNc-treated samples. * = P < 0.05. See Figure 1 for other definitions.
B27 that accumulated with IFNc treatment were reduced at least 50%, whereas accumulation of monomers was not significantly changed ( Figure 4 ). Rapamycin also reduced 40% of BiP-bound HLA-B27 heavy chains ( Figure 4 ). Rapamycin is also effective at reducing dimers and oligomers of HLA-B27 in cells treated with IFNc for 20-24 hours (Colbert RA, et al: unpublished observations).
Cell surface b 2 m-free HLA-B27 heavy chains have been implicated in triggering killer cell immunoglobulin-like receptors on CD4+ Th17 T cells (2) . To assess the effect of autophagy on cell surface HLA-B27, macrophages were incubated with IFNc for 24 hours; rapamycin was added for the final 2-4 hours to activate autophagy. Cells were then washed and stained with either HC10 (to detect free HLA-B27 heavy chains) or ME1 (to measure folded HLA-B27 complexes) and analyzed by flow cytometry. Rapamycin treatment led to a rapid, time-dependent reduction in free HLA-B27 heavy chains on the cell surface of IFNc-treated cells ( Figure 5A ). In contrast, rapamycin had no significant effect on folded HLA-B27 complexes ( Figure 5B ). These data indicate that activating autophagy can promote selective elimination of dimeric and oligomeric HLA-B27 heavy chains that accumulate with IFNc treatment and indicate that activating this pathway might be a beneficial strategy to ameliorate effects of HLA-B27 misfolding.
DISCUSSION
In the current study, we investigated whether autophagy plays a role in the degradation of misfolded HLA-B27 heavy chains. Our results show that blocking autophagy for 3 hours led to accumulation of disulfide-linked HLA-B27 dimers and oligomers, as well as monomers, in primary cells from HLA-B27-transgenic rats after HLA-B27 up-regulation, and in transfected cells (C1R.B27) that continually express HLA-B27 heavy chains. Furthermore, a substantial proportion of accumulating HLA-B27 heavy chains are bound to the ER chaperone BiP, which has been shown to accumulate primarily with dimers of HLA-B27 (16) . Importantly, we showed that activating autophagy with rapamycin led to a substantial and rapid reduction (50% in 2 hours) in the amount of misfolded HLA-B27 dimers and oligomers, including BiP-bound HLA-B27 heavy chains.
Activation imposed by the exogenous stimulus (rapamycin) was more selective for the degradation of misfolded HLA-B27 (dimers and oligomers) than for monomers. However, it should be noted that in some experiments, we observed a reduction in HC10-reactive monomers along with more striking decreases (>50%) in dimers and oligomers, suggesting that autophagy is not entirely selective for misfolded forms (Colbert RA, et al: unpublished observations). Experimental variation in the strength of autophagy activation may account for these differences. Taken together, these results implicate autophagy as an ERQC pathway involved in the elimination of misfolded and BiP-bound forms of HLA-B27. Rapamycin also reduced free HLA-B27 heavy chains on the cell surface ( Figure 5 ), which is not expected to be a consequence of ERQC. However, free HLA class I heavy chains recycle through endosomes (2) , and recycling endosomes contribute to autophagosome formation (43) , suggesting a plausible mechanism for enhanced removal of free HLA-B27 heavy chains from the cell surface.
ERAD of HLA class I was first demonstrated for heavy chains synthesized when b 2 m or peptide is limited (44) . HLA-B27 heavy chains were shown to undergo ERAD even in the presence of b 2 m and peptide, providing evidence for misfolding under normal physiologic conditions (4). HLA-B27 misfolding is a consequence of delayed folding imparted by polymorphic amino acids that also reduce its affinity for peptides and promote dimerization in the ER (4-6). Since publication of these early studies, much more has been learned about ERAD of HLA class I heavy chains in general and HLA-B27 in particular. EDEM1, together with the E3 ubiquitin ligase HRD-1 and ubiquitin-conjugating enzyme E2 J1, orchestrate the recognition, dislocation, and ubiquitination of misfolded heavy chains, including HLA-B27 dimers (21, 22) . Furthermore, manipulation of the ERAD pathway, either by overexpressing EDEM1 or by preconditioning the ER with agents that activate the unfolded protein response, enhances the disposal of HLA-B27 dimers (22) .
Our studies confirm and extend previous results using transfected cells by showing that ERAD plays a role in quality control of HLA-B27 after up-regulation in rat primary macrophages. In rat macrophages, blocking ERAD was slightly more effective at forcing the accumulation of HLA-B27 heavy chains compared with blocking autophagy. However, the opposite was seen in C1R cells expressing HLA-B27. Barring differences in the sensitivity Figure 5 . Effect of activating autophagy on cell surface HLA-B27 free heavy chain. Bone marrow-derived macrophages were incubated without or with interferon-c (IFNc) (50 ng/ml) for 24 hours, followed by treatment without or with rapamycin (25 lM) for the last 2 hours (Ra-2h) or 4 hours (Ra-4h). Cells were stained with allophycocyaninconjugated HC10 (HC) to detect free heavy chains (A) or with Pacific Blue-conjugated ME1 to detect folded HLA-B27 (B). Bars show the mean AE SEM (n = 4 independent experiments). MFI = mean fluorescence intensity. ** = P < 0.005. of primary macrophages and C1R (B lymphoblastoid) cells to these inhibitors, this suggests that there is a difference in the trafficking of misfolded HLA-B27 through these 2 pathways. This could be attributable to a number of factors, including cell type-specific differences in ERQC components or, perhaps, differences in baseline expression of HLA-B27. The C1R.B27 cells continually express a protein that misfolds, which can be detrimental to survival. In contrast, rat macrophages are derived from BM progenitors in vitro in the absence of exogenous stimuli that up-regulate HLA class I, and thus HLA-B27 expression is relatively low until the cells are exposed to IFNc. It will be of interest to compare the relative contributions of ERAD and autophagy to ERQC of HLA-B27 in other cells derived from HLA-B2-transgenic rats.
HLA-B27 dimers form immediately after heavy chains are synthesized in the ER (5), exhibit a half-life exceeding 8 hours (22) , and can be found in many cells at steady state (5, 18, 22) , which suggests that they are not efficiently eliminated and may be resistant to ERAD. This is in sharp contrast to many proteins that misfold in the ER and are efficiently degraded by ERAD, including major histocompatibility complex class I heavy chains produced in the absence of b 2 m or peptide (21, 44) . This raises the question of why HLA-B27 heavy chain dimers and oligomers are not efficiently degraded. By comparing how rat cells dispose of excess HLA-B27 heavy chains compared with HLA-B7, our study demonstrates that dimers of HLA-B27 are poorly ubiquitinated relative to HLA-B7 (monomers). This is apparent even in IFNc-treated cells in the absence of autophagy or ERAD inhibitors ( Figure 3D ). There is precedent for this, because mutations in T cell receptor a that increase the formation of disulfide-linked homo-oligomers also prevent it from being degraded by ERAD (45) . Thus, we hypothesize that rapid dimerization of HLA-B27 heavy chains is an impediment to efficient ERAD and contributes to accumulation of misfolded forms.
Autophagy has been implicated in ERQC of several proteins, including the mutant a 1 -antitrypsin Z variant (ATZ). AT is normally produced and secreted in large amounts from the ER of hepatocytes and functions as a serine protease inhibitor that limits proteolytic damage to tissues, particularly during inflammation (30) . A single point mutation in ATZ causes it to misfold and polymerize, forming insoluble aggregates in the extended ER. These insoluble aggregates are resistant to dislocation from the ER and thus do not undergo ERAD but are degraded by autophagy. A second ERQC autophagy pathway has been described for nonaggregated, ERADresistant membrane proteins (31) , with gonadotropinreleasing hormone receptor type I mutants as model substrates. Two different gonadotropin-releasing hormone receptor type I mutants are subjected to ERQC, but degradation of one is blocked by proteasome inhibitors, while the other is blocked by inhibitors of autophagy. Misfolded proteins that cannot be cleared by the proteosomal pathway can activate the autophagy pathway for degradation (46) .
In summary, results of the current study implicate autophagy as well as ERAD in ERQC of misfolded HLA-B27. Nevertheless, neither the autophagy nor the proteasome pathway was sufficient under these conditions to prevent misfolded HLA-B27 from accumulating. In contrast to the proteasome pathway, the autophagy pathway can be further stimulated by starvation or the use of chemicals that inhibit the mTOR pathway (28) . Several studies successfully used the mTOR inhibitor rapamycin in neurodegenerative diseases such as Huntington's disease or Alzheimer's disease to partially resolve the misfolding proteins such as tau by further activating autophagy (29, 47, 48) , and it is widely used as an immunosuppressant to prevent transplant rejection. Thus, we treated cells with rapamycin for 2 hours during up-regulation of HLA-B27 or HLA-B7. Interestingly, mainly dimers and oligomers of HLA-B27 were reduced by activating autophagy, including heavy chains bound to BiP. Moreover, rapamycin was able to eliminate a significant proportion of cell surface-free HLA-B27 heavy chains, which represent aberrant forms of HLA-B27 that are implicated in triggering CD4+ Th17 Tcells to produce IL-17 (2) . Therefore, these results raise the possibility that rapamycin could be tested therapeutically, although this remains a challenge, because autophagy is involved in multiple homeostatic pathways inside and outside of the immune system.
